Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.
Royalty Pharma (RPRX) is poised to become a quiet winner from Revolution Medicines (RVMD) and its pancreatic cancer drug daraxonrasib, which recently received FDA approval. Royalty Pharma has invested in Revolution Medicines and stands to earn substantial royalties if the drug proves successful. With the potential for peak revenues of up to $11 billion, Royalty Pharma's gains could be significant without the need for further investment or involvement in drug development.
In contrast to Revolution Medicines, which has been losing money on its drug development investments, Royalty Pharma offers a diversified portfolio of approved and developing drugs, boasting 35 approved patents and 16 in the blockbuster category, along with 16 additional drugs in various stages of development. This provides a more stable and diversified revenue stream compared to focusing on a single drug.
While Revolution Medicines' stock has surged 200% over the past year and 700% over three years, the stock's growth story could be cooling as Wall Street has already factored in the positive FDA approval news. However, Royalty Pharma's 1.4% dividend yield offers an attractive alternative for investors seeking both growth potential and steady income.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
